Your browser doesn't support javascript.
loading
Case report: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, associated with a germline mutation in PMS2.
Merchant, Mythili; Raygada, Margarita; Pang, Ying; Quezado, Martha; Raffeld, Mark; Xi, Liqiang; Kim, Jung; Tyagi, Manoj; Abdullaev, Zied; Kim, Olga; Sergi, Zach; Pillai, Tina; Ozer, Byram; Zaghloul, Kareem; Heiss, John D; Armstrong, Terri S; Gilbert, Mark R; Aldape, Kenneth; Wu, Jing.
Afiliação
  • Merchant M; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
  • Raygada M; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
  • Pang Y; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
  • Quezado M; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
  • Raffeld M; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
  • Xi L; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
  • Kim J; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
  • Tyagi M; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
  • Abdullaev Z; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
  • Kim O; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
  • Sergi Z; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
  • Pillai T; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
  • Ozer B; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
  • Zaghloul K; Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD, United States.
  • Heiss JD; Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD, United States.
  • Armstrong TS; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
  • Gilbert MR; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
  • Aldape K; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
  • Wu J; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
Front Oncol ; 12: 954879, 2022.
Article em En | MEDLINE | ID: mdl-35982947
ABSTRACT
Most tumors, including brain tumors, are sporadic. However, a small subset of CNS tumors are associated with hereditary cancer conditions like Lynch Syndrome (LS). Here, we present a case of an oligodendroglioma, IDH-mutant and 1p/19q-codeleted, and LS with a germline pathogenic PMS2 mutation. To our knowledge, this has only been reported in a few cases in the literature. While the family history is less typical of LS, previous studies have indicated the absence of a significant family history in patient cohorts with PMS2 mutations due to its low penetrance. Notably, only a handful of studies have worked on characterizing PMS2 mutations in LS, and even fewer have looked at these mutations in the context of brain tumor development. This report aims to add to the limited literature on germline PMS2 mutations and oligodendrogliomas. It highlights the importance of genetic testing in neuro-oncology.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article